Cerebrospinal fluid markers in the differentiation of molecular subtypes of sporadic Creutzfeldt-Jakob disease

European Journal of Neurology

Volumn 23, Issue 6, 2016, Pages 1126-1133

  Gmitterova K ^a,b   Heinemann, U ^a   Krasnianski, A ^a,c   Gawinecka, J ^a,d   Zerr, I ^a  

^a UNIVERSITY MEDICAL CENTER GÖTTINGEN   (Germany)

^b Faculty of Natural Sciences   (Slovakia)

^c GOETHE UNIVERSITY   (Germany)

^d UNIVERSITY HOSPITAL ZURICH   (Switzerland)

Author keywords

Cerebrospinal fluid; Creutzfeldt Jakob disease; Neuron specific enolase; S100B; Tau

Indexed keywords

BIOLOGICAL MARKER; NEURON SPECIFIC ENOLASE; PROTEIN S100B; TAU PROTEIN; ENOLASE;

ADULT; AGED; ARTICLE; CEREBROSPINAL FLUID ANALYSIS; CODON; DISEASE CLASSIFICATION; DISEASE DURATION; FEMALE; GENOTYPE; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROTEIN CEREBROSPINAL FLUID LEVEL; SPORADIC CREUTZFELDT JAKOB DISEASE; CELL DIFFERENTIATION; CEREBROSPINAL FLUID; CREUTZFELDT JAKOB DISEASE; DIFFERENTIAL DIAGNOSIS; GENETICS; MIDDLE AGED; PHOSPHORYLATION; VERY ELDERLY; YOUNG ADULT;

ADULT; AGED; AGED, 80 AND OVER; BIOMARKERS; CELL DIFFERENTIATION; CREUTZFELDT-JAKOB SYNDROME; DIAGNOSIS, DIFFERENTIAL; FEMALE; GENOTYPE; HUMANS; MALE; MIDDLE AGED; PHOSPHOPYRUVATE HYDRATASE; PHOSPHORYLATION; TAU PROTEINS; YOUNG ADULT;

EID: 84963575352     PISSN: 13515101     EISSN: 14681331     Source Type: Journal    
DOI: 10.1111/ene.12991     Document Type: Article

References (23)

1. Parchi P, Giese A, Capellari S, et al. Classification of sporadic Creutzfeldt-Jakob disease based on molecular and phenotypic analysis of 300 subjects. Ann Neurol 1999; 46: 224-233.
2. Collins SJ, Sanchez-Juan P, Masters CL, et al. Determinants of diagnostic investigation sensitivities across the clinical spectrum of sporadic Creutzfeldt-Jakob disease. Brain 2006; 129: 2278-2287.
3. Sanchez-Juan P, Sanchez-Valle R, Green A, et al. Influence of timing on CSF tests value for Creutzfeldt-Jakob disease diagnosis. J Neurol 2007; 254: 901-906.
4. Karch A, Hermann P, Ponto C, et al. Cerebrospinal fluid tau levels are a marker for molecular subtype in sporadic Creutzfeldt-Jakob disease. Neurobiol Aging 2015; 36: 1964-1968.
5. Hsich G, Kenney K, Gibbs CJ Jr, Lee KH, Harrington MG. The 14-3-3 brain protein in cerebrospinal fluid as a marker for transmissible spongiform encephalopathies. N Engl J Med 1996; 335: 924-930.
6. Van Everbroeck B, Quoilin S, Boons J, Martin JJ, Cras P. A prospective study of CSF markers in 250 patients with possible Creutzfeldt-Jakob disease. J Neurol Neurosurg Psychiatry 2003; 74: 1210-1214.
7. Perry DC, Geschwind MD. Thorough work-up and new diagnostic criteria needed for CJD. Nat Rev Neurol 2011; 7: 479-480.
8. Kenney K, Brechtel C, Takahashi H, Kurohara K, Anderson P, Gibbs CJ Jr. An enzyme-linked immunosorbent assay to quantify 14-3-3 proteins in the cerebrospinal fluid of suspected Creutzfeldt-Jakob disease patients. Ann Neurol 2000; 48: 395-398.
9. Otto M, Wiltfang J, Cepek L, et al. Tau protein and 14-3-3 protein in the differential diagnosis of Creutzfeldt-Jakob disease. Neurology 2002; 58: 192-197.
10. Sanchez-Juan P, Green A, Ladogana A, et al. CSF tests in the differential diagnosis of Creutzfeldt-Jakob disease. Neurology 2006; 67: 637-643.
11. Bahl JM, Heegaard NH, Falkenhorst G, et al. The diagnostic efficiency of biomarkers in sporadic Creutzfeldt-Jakob disease compared to Alzheimer's disease. Neurobiol Aging 2009; 30: 1834-1841.
12. Skillbäck T, Rosén C, Asztely F, Mattsson N, Blennow K, Zetterberg H. Diagnostic performance of cerebrospinal fluid total tau and phosphorylated tau in Creutzfeldt-Jakob disease: results from the Swedish Mortality Registry. JAMA Neurol 2014; 71: 476-483.
13. Varges D, Jung K, Gawinecka J, et al. Amyloid-( 1-42 levels are modified by apolipoprotein E ε4 in Creutzfeldt-Jakob disease in a similar manner as in Alzheimer's disease. J Alzheimers Dis 2011; 23: 717-726.
14. Gmitterová K, Heinemann U, Bodemer M, et al. 14-3-3 CSF levels in sporadic Creutzfeldt-Jakob disease differ across molecular subtypes. Neurobiol Aging 2008; 30: 1842-1850.
15. WHO. Diagnostic Tests for Human Transmissible Spongiform Encephalopathies. WHO Manual for Surveillance of Human Transmissible Spongiform Encephalopathies including variant Creutzfeldt-Jakob disease. Genova: Communicable Disease Surveillance and Response World Health Organisation, 2003: 51-59.
16. Schulz-Schaeffer WJ, Fatzer R, Varidevelde M, Kretzschmar HA. Detection of PrP(Sc) in subclinical BSE with the paraffin-embedded tissue (PET) blot. Arch Virol 2000; 16: 173-180.
17. Windl O, Giese A, Schulz-Schaeffer W, et al. Molecular genetics of human prion diseases in Germany. Hum Genet 1999; 105: 244-252.
18. Beaudry P, Cohen P, Brandel JP, et al. 14-3-3 protein, neuron-specific enolase, and S-100 protein in cerebrospinal fluid of patients with Creutzfeldt-Jakob disease. Dement Geriatr Cogn Disord 1999; 10: 40-46.
19. Parchi P, Strammiello R, Notari S, et al. Incidence and spectrum of sporadic Creutzfeldt-Jacob disease variants with mixed phenotype and co-occurrence of PrP(Sc) types: an updated classification. Acta Neuropathol 2009; 118: 659-671.
20. Parchi P, de Boni L, Saverioni D, et al. Consensus classification of human prion disease histotypes allows reliable identification of molecular subtypes: an inter-rater study among surveillance centres in Europe and USA. Acta Neuropathol 2012; 124: 517-529.
21. Llorens F, Zafar S, Ansoleaga B, et al. Subtype and regional regulation of prion biomarkers in sporadic Creutzfeldt-Jakob disease. Neuropathol Appl Neurobiol 2015; 41: 631-645.
22. Llorens F, Lopez-Gonzalez I, Thüne K, et al. Subtype and regional specific neuroinflammation in sporadic Creutzfeldt-Jakob disease. Front Aging Neurosci 2014; 6: 198.
23. Jimi T, Wakayama Y, Shibuya S, et al. High levels of nervous system-specific proteins in cerebrospinal fluid in patients with early stage Creutzfeldt-Jakob disease. Clin Chim Acta 1992; 211: 37-46.